Viroscience Department, Erasmus Medical Center, Rotterdam, the Netherlands.
Viroscience Department, Erasmus Medical Center, Rotterdam, the Netherlands.
Curr Opin Virol. 2023 Oct;62:101349. doi: 10.1016/j.coviro.2023.101349. Epub 2023 Aug 28.
SARS coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, emerged in China in December 2019. Vaccines developed were very effective initially, however, the virus has shown remarkable evolution with multiple variants spreading globally over the last three years. Nowadays, newly emerging Omicron lineages are gaining substitutions at a fast rate, resulting in escape from neutralization by antibodies that target the Spike protein. Tools to map the impact of substitutions on the further antigenic evolution of SARS-CoV-2, such as antigenic cartography, may be helpful to update SARS-CoV-2 vaccines. In this review, we focus on the antigenic evolution of SARS-CoV-2, highlighting the impact of Spike protein substitutions individually and in combination on immune escape.
严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）是导致 COVID-19 的病原体，于 2019 年 12 月在中国出现。最初开发的疫苗非常有效，然而，在过去三年中，该病毒发生了显著的进化，出现了多种变体在全球范围内传播。如今，新出现的奥密克戎谱系正在快速获得取代，从而逃避针对刺突蛋白的中和抗体的中和。用于绘制取代对 SARS-CoV-2 进一步抗原进化影响的工具，如抗原绘图，可能有助于更新 SARS-CoV-2 疫苗。在这篇综述中，我们重点关注 SARS-CoV-2 的抗原进化，强调刺突蛋白取代单独和组合对免疫逃逸的影响。
